Topos Bio CEO Ryan Zarcone explains why designing drugs for Parkinson's and Alzheimer's is almost impossible for humans, but a perfect problem for AI: "When a chemist designs a drug for a protein, the model is static. I have this protein, it has a shape, and I’m trying to fill that shape with a drug." "These really dynamic proteins, like those involved in Parkinson’s and Alzheimer’s, don’t have one shape. They have potentially thousands of different shapes that they’re constantly…